Small Molecule Therapeutics
Category VIEW ALL
Selective inhibitors of vancomycin-resistant enterococcus
Technology No. 2026-FLAH-71325
Discovery of highly potent HIV-1 protease inhibitors with polycyclic-THF ligands
Technology No. 2020-GHOS-68891
Immunotherapy of Glioblastoma with Multi-functional NK Cells in Combination with Inhibition of Autophagy
Technology No. 2020-MATO-68833
Carbonic Anhydrase Inhibitors for Treatment of Neisseria Gonorrhoeae
Technology No. 2020-FLAH-68832
Novel Pyrimidinones Targeting Adenylyl Cyclase 1 for Treating Chronic Pain
Technology No. 2020-FLAH-68825
Tannic Acid-based Nanocapsules for Sustained Delivery of Immunogenic Cell Death Inducers
Technology No. 2020-YEO-68760
Small Molecule Stimulators of the Core Particle of the Proteasome
Technology No. 2020-TRAD-68744
CF3-, OCF3-, SCF3- and SF5-containing Antibacterial Agents
Technology No. 2019-SINT-68535
Immunomodulatory and Potent Anticancer Activity of Selective Steroidal Analogs
Technology No. 2019-CHOP-68534
Discovery of Highly Potent HIV-1 Protease Inhibitors with Crown-THF Ligands
Technology No. 2019-GHOS-68467
Small Molecules for Treating Vancomycin Resistant Enterococcus Infections
Technology No. 2019-FLAH-68419
Unnatural Proline-rich Antimicrobial Peptides Targeting Intracellular Pathogenic Bacteria and Antibiotic Conjugates Thereof
Technology No. 2019-CHMI-68405
Nanoparticles for Sepsis Treatment
Technology No. 2019-YEO-68355
New Target Identified for Cancer Therapy and Its Inhibitor
Technology No. 2018-DAI-68268
Repurposed Drug for Clostridium Difficile Infection
Technology No. 2018-SELE-68251
Novel Inhalation Formulations of Colistin and Meropenem
Technology No. 2018-ZHOU-68233
Targeted Antimicrobial Photodynamic Therapy using GaPpIX Conjugates
Technology No. 2018-WEI-68200
N-(1,3,4-oxadiazol-2-yl)benzamide antibacterial agents
Technology No. 2018-SINT-68199
Novel Selective Inhibitors for Protein alpha-N-terminal Methyltransferases
Technology No. 2018-HUAN-68180
Arylnapthalene Vacuolar-ATPase Inhibitors as Anti-viral Agents
Technology No. 2018-DAVI-68178
Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors
Technology No. 2018-CUSH-68109
Cleavable Conjugates of Antibiotics and an Antibacterial Cell-Penetrating Peptide
Technology No. 2018-CHMI-68009
Novel Scaffold of Adenyly Cyclase Inhibitors for Chronic Pain and Opioid Dependence
Technology No. 2017-WATT-67991
Novel Macrocyclic HIV-1 Protease Inhibitors to Combat Multidrug-Resistant HIV-1 Variants
Technology No. 2017-GHOS-67965
Synthesis and Antimicrobial Activity of Novel Lactones
Technology No. 2017-DAI-67879
Novel Adenyly Cyclase Inhibitors for Chronic Pain and Opioid Dependence
Technology No. 2017-WATT-67867
Dual Kinase/demethylase as Inhibitors of Proliferative Diseases
Technology No. 2017-SINT-67825
Discovery and Design of Selective Ubiquitin Specific Protease (USP) Inhibitors
Technology No. 2017-PEPE-67704
Novel Tricyclic P2-Ligand Containing Potent HIV-Protease Inhibitor Against HIV/AIDS
Technology No. 2017-GHOS-67663
4-substituted-3-isoquinoline Amides and Amidines as Anticancer Agents
Technology No. 2016-SINT-67603
Albumin-coated Nanocrystals
Technology No. 2016-YEO-67581
Enantioselective Total Synthesis of Both Antipodes in the Proposed Structure of Macrolide Cytotoxic Agent Callyspongiolide
Technology No. 2016-GHOS-67560
Pyrimidinephenylthiazoles as Antimicrobials
Technology No. 2016-CUSH-67515
A Chimeric EGF-Targeted Bacterial Toxin as Therapeutic Agent Against Bladder Cancer
Technology No. 2016-AGUI-67476
Broad-Spectrum Non-Covalent Anti-Coronavirus Therapeutics for Implementation in Zoonotic Outbreaks
Technology No. 2016-STJO-67409
Peptoid Linked Fragments as PIP Box Antagonists
Technology No. 2016-DAVI-67362
Aryl Isonitriles as A New Class of Antimicrobial Compounds
Technology No. 2015-DAI-67104
Repurposing Nonantimicrobial Drugs to Treat Bacterial Infections
Technology No. 2015-SELE-67097
Adenylyl Cyclase Inhibitors for Neuropathic and Inflammatory Pain Treatment
Technology No. 2015-DAI-67035
A Chimeric EGF-Targeted Bacterial Toxin as Therapeutic Agent against Bladder Cancer
Technology No. 2014-AGUI-66886
Dual Action, Unnatural Proline-rich Peptides Target Elusive Intracellular Pathogenic Bacteria
Technology No. 2014-CHMI-66831
A Class of Exceptionally Potent HIV-1 Protease Inhibitors Containing Novel Bridged Tp-THF and Other Variants as P2-ligands
Technology No. 2014-GHOS-66828
Novel Anticancer Compounds
Technology No. 2014-GHOS-66703
Compounds and Methods for Treating HIV
Technology No. 2014-GHOS-66624
Inhibition of Memapsin 1 Cleavage in the Treatment of Diabetes
Technology No. 2013-GHOS-66610
Antimicrobial Activity of Novel Substituted Thiazoles Against Methicillin-Resistant Staphylococcus Aureus (MRSA)
Technology No. 2013-CUSH-66348
Chitosan Derivative for Endotoxin Inactivation
Technology No. 65894
Indenoisoquinoline Topoisomerase I Inhibitors Substituted with Carbohydrates
Technology No. 65707
HIV-1 Protease Inhibitors Fused Tris-Tetrahydrofuran (Tris-THF) as P2-ligand
Technology No. 65566
2nd Generation FT Inhibitors
Technology No. 64935
Potent Dimerization Inhibitors for HIV-1 Protease
Technology No. 64554
5/5-5/6-BISARYL COMPOUNDS AS TRANSFORMING GROWTH FACTOR-β ACTIVATED KINASE, TAK1, INHIBITORS
Technology No. 2025-SINT-70883
Software to generate mega chemical library
Technology No. 2025-LI-70824
carbonic anhydrase leads for treatment of bacterial infections
Technology No. 2025-FLAH-71261
Targeting Cdc14 phosphatase for anti-fungal agents
Technology No. 2024-ZHAN-70728
SHP2 Degraders for Anti-cancer Therapy
Technology No. 2024-ZHAN-70417
TC-PTP/PTPN2 Degraders for Cancer Immunotherapy
Technology No. 2024-ZHAN-70394
PDE Stable Endo-phosphorothioate Substituted 2'3'-cGAMP Analogues as STING Agonist
Technology No. 2024-SINT-70418
5-6-5/6 Scaffold as Selective Kinase Inhibitor Moiety with Low Activity Against Immune and Cardiovascular Anti-targets
Technology No. 2024-SINT-70378
5/6-5/6-Bisaryl Substituted with Saturated Cyclic Heterocycles as TAK1 Inhibitors
Technology No. 2024-SINT-70377
Discovery of cyclic peptide natural product inhibitors of free living amoeba
Technology No. 2024-PARK-70715
Analogs of Diphyllin
Technology No. 2024-DAVI-70723
PTP1B/TC-PTP Dual Protein Degraders
Technology No. 2023-ZHAN-70087
Combination of Phosphatidyl Serine Blockade and STING Stimulation for Cancer Immunotherapy
Technology No. 2023-YEO-70023
3H-pyrazolo[4,3-f]quinoline-based Compounds as STING Antagonists
Technology No. 2023-SINT-70181
![3H-pyrazolo[4,3-f]quinoline-based Compounds as STING Antagonists](https://storage.googleapis.com/elucid3-storage-1-us/uw/product/13269/2/3h-pyrazolo43-fquinoline-based-compounds-as-sting-antagonists-01.png?mtime=20251201115737)
Inhibitors of Solvent Front Mutated RET Kinase
Technology No. 2023-SINT-70021
Cyclic Peptide Stimulators of the Proteasome
Technology No. 2023-PARK-70287
Nrf2 Based Stapled Peptides for Sensitization of Cancers to Chemotherapeutics
Technology No. 2023-PARK-69958
Prodrugs of Nicotinamide N-Methyltransferase (NNMT) Inhibitors as Novel Therapeutic Agents
Technology No. 2023-HUAN-70285
Designing HIV-1 Protease Inhibitors Using Imatinib & Nilotinib Templates for Effective HIV/AIDS Treatment
Technology No. 2023-GHOS-70150
Bacterial Carbonic Anhydrase Inhibitors with Improved Pharmacokinetics and Efficacy
Technology No. 2023-FLAH-70278
Natural Product-Inspired Molecules for Covalent Inhibition of SHP2 Tyrosine Phosphatase
Technology No. 2023-DAI-70254
CAR-neutrophils Produced In Vivo to Treat Cancer
Technology No. 2023-BAO-70025
Treatment of Lowe Syndrome
Technology No. 2023-AGUI-69998
Immunoactive Nanocarrier of Immunogenic Cell Death Inducers
Technology No. 2022-YEO-69546
Continuous Flow Synthesis of Lorazepam
Technology No. 2022-THOM-69904
Benzamide or N-hydroxybenzamide Kinase Inhibitors Derived from Doebner-Povarov Reaction
Technology No. 2022-SINT-69859
Nicotinamide-based Compounds as Potent Inhibitors of Translational- and Transcriptional-related Kinases
Technology No. 2022-SINT-69726
Enhanced Cell-potent Peptidomimetic Inhibitors for NTMT1/2
Technology No. 2022-HUAN-69636
PROTEIN:PROTEIN INTERACTION INHIBITORS
Technology No. 2022-HU-69918
Highly Efficient and Optically Active Synthesis of Crown-THF Ligand
Technology No. 2022-GHOS-69804
Potent 2420-Class of Protease Inhibitors for Treatment of COVID-19
Technology No. 2022-GHOS-69733
Potent Protease Inhibitors for Treatment of COVID-19
Technology No. 2022-GHOS-69724
Design and Synthesis of bi-aryl Methylated Lactam Derivatives to Inhibit the BRD7 Bromodomain Function in Prostate Cancer
Technology No. 2022-DYKH-69819
Cyanide Countermeasures
Technology No. 2022-DAVI-69921
Polymyxin Combinational Formulations
Technology No. 2021-ZHOU-69256
Inhibitors of Cyclic Mononucleotide and Cyclic Dinucleotide Phosphodiesterases
Technology No. 2021-SINT-69252
Antibiotic Discovery via BICyCLE (Biologically Inspired Chemically Created Leads)
Technology No. 2021-PARK-69383
Cell-potent and Selective Inhibitors for Nicotinamide N-methyltransferase
Technology No. 2021-HUAN-69352
COMPOUNDS FOR THE TREATMENT OF SARS
Technology No. 2021-GHOS-69511
Design and Synthesis of Novel SARS-CoV-2 3C Inhibitors
Technology No. 2021-GHOS-69510
Tris-Amide Based Novel Anti-COVID-19 Compounds
Technology No. 2021-GHOS-69492
MODIFIED Discovery of Potent anti-Mpro Inhibitors for Covid-19 Treatment using Alpha-ketoamide Derivatives
Technology No. 2021-GHOS-69205
Targeting BRAT1 with Curcusone Diterpenoids and Analogs for Cancer Treatment
Technology No. 2021-DAI-69235
Novel Amination Method for Medicinally Important Compounds
Technology No. 2021-DAI-69172
Nano-composite Microparticles with Ivacaftor and Colistin
Technology No. 2020-ZHOU-68954
Quinolone-based Inhibitors of Lymphoid Tyrosine Phosphatase (PTPN22)
Technology No. 2020-ZHAN-68996
N-aryl oxamic acid based inhibitors for Mycobacterium Tuberculosis Protein Tyrosine Phosphatase B (mPTPB)
Technology No. 2020-ZHAN-68995
Griseofulvin Formulation for Therapy of Wet Macular Degeneration
Technology No. 2020-YEO-69132
Tetrahydro-3H-pyrazolo[4,3-f]quinolone and tetrahydro-3H-pyrrolo[3,2-f]quinoline -Containing Compounds as Anticancer Agents
Technology No. 2020-SINT-69102
![Tetrahydro-3H-pyrazolo[4,3-f]quinolone and tetrahydro-3H-pyrrolo[3,2-f]quinoline -Containing Compounds as Anticancer Agents](https://storage.googleapis.com/elucid3-storage-1-us/uw/product/13208/2/tetrahydro-3h-pyrazolo43-fquinolone-and-tetrahydro-3h-pyrrolo32-fquinoline--containing-compounds-as-anticancer-agents-01.png?mtime=20251202162718)
2,3-Disubstituted pyrido[3,4-b]pyrazine-containing Compounds as Kinase Inhibitors
Technology No. 2020-SINT-69073
![2,3-Disubstituted pyrido[3,4-b]pyrazine-containing Compounds as Kinase Inhibitors](https://storage.googleapis.com/elucid3-storage-1-us/uw/product/13207/2/23-disubstituted-pyrido34-bpyrazine-containing-compounds-as-kinase-inhibitors-01.png?mtime=20251202163126)
Discovery of Potent Protease Inhibitors for Covid-19 Treatment using Specifically Designed Novel bis-amide Derivatives
Technology No. 2020-GHOS-69088
Discovery of Potent Anti-Mpro Inhibitors for Covid-19 Treatment using Alpha-ketoamide Derivatives
Technology No. 2020-GHOS-69045
Discovery of Potent Anti-Mpro Inhibitors for Covid-19 Treatment
Technology No. 2020-GHOS-69034
NOVEL COMPOUNDS FOR IMMUNOMODULATORY ACTIVITY
Technology No. 2020-CHOP-68949
Therapeutic Strategy by Drug Repositioning against Lowe Syndrome
Technology No. 2017-AGUI-67722
